Xeris Pharmaceuticals | XERS - Current Liabilities

Stock Price
6.24
Daily Change
-0.14 -2.19%
Monthly
1.96%
Yearly
27.87%
Q2 Forecast
6.39

Xeris Pharmaceuticals reported $118.59M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Celltrion KRW 283.62B 3.72T Dec/2025
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 38.28M 7.55M Mar/2026
Divis Laboratories Ltd INR 17.28B 2.76B Sep/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Kangmei Pharma CNY 5.81B 57.93M Sep/2025
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 5.56M 2.26M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neuren Pharmaceuticals AUD 4.34M 3.58M Dec/2025
Organigram Holdings CAD 94.05M 32.11M Dec/2025
Ovoca Bio EUR 186K 2.26M Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pharma Mar EUR 89.23M 4.65M Mar/2026
Qiagen NV USD 512.14M 461.26M Dec/2025
Sartorius EUR 2.11B 145.8M Mar/2026
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Supernus Pharmaceuticals USD 373.93M 35.76M Mar/2026
Tilray USD 259.32M 8.32M Sep/2025
Zealand Pharma A/S 664.96M 513.61M Dec/2025
Zz Pientze Pharmaceu CNY 2.28B 134.52M Mar/2026